BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12867217)

  • 1. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
    Blum RA; Majumdar A; McCrea J; Busillo J; Orlowski LH; Panebianco D; Hesney M; Petty KJ; Goldberg MR; Murphy MG; Gottesdiener KM; Hustad CM; Lates C; Kraft WK; Van Buren S; Waldman SA; Greenberg HE
    Clin Ther; 2003 May; 25(5):1407-19. PubMed ID: 12867217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
    Shah AK; Hunt TL; Gallagher SC; Cullen MT
    Curr Med Res Opin; 2005 Apr; 21(4):595-601. PubMed ID: 15899109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
    Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
    McCrea JB; Majumdar AK; Goldberg MR; Iwamoto M; Gargano C; Panebianco DL; Hesney M; Lines CR; Petty KJ; Deutsch PJ; Murphy MG; Gottesdiener KM; Goldwater DR; Blum RA
    Clin Pharmacol Ther; 2003 Jul; 74(1):17-24. PubMed ID: 12844131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
    Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
    Momper JD; Heinrichs MT; Krudys K; Griebel D; Kumar S; Kim I; Mehrotra N; Mulberg AE; Garimella N; Nelson R; Reaman G; Sinha V; Yao L; Zineh I; Burckart G; Sachs H; Mulugeta Y
    J Clin Pharmacol; 2020 Jun; 60(6):775-784. PubMed ID: 31967340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant.
    Stoch SA; Gargano C; Valentine J; Braun MP; Murphy MG; Fedgchin M; Majumdar A; Pequignot E; Gottesdiener KM; Petty KJ; Panebianco D; Dean D; Kraft WK; Greenberg HE
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1313-21. PubMed ID: 20734049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration.
    Corrigan BW; Nicholls B; Thakrar B; Lam R; Grosse C; Alianti J; Palmer JL
    Drug Metab Dispos; 1999 Jan; 27(1):110-2. PubMed ID: 9884318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant.
    Bergman AJ; Marbury T; Fosbinder T; Swan S; Hickey L; Bradstreet TE; Busillo J; Petty KJ; Aiyer KJ; Constanzer M; Huskey SE; Majumdar A
    Clin Pharmacokinet; 2005; 44(6):637-47. PubMed ID: 15910011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.
    Majumdar AK; McCrea JB; Panebianco DL; Hesney M; Dru J; Constanzer M; Goldberg MR; Murphy G; Gottesdiener KM; Lines CR; Petty KJ; Blum RA
    Clin Pharmacol Ther; 2003 Aug; 74(2):150-6. PubMed ID: 12891225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting.
    Howell J; Smeets J; Drenth HJ; Gill D
    J Oncol Pharm Pract; 2009 Dec; 15(4):223-31. PubMed ID: 19304880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
    Ottoboni T; Keller MR; Cravets M; Clendeninn N; Quart B
    Drug Des Devel Ther; 2018; 12():429-435. PubMed ID: 29535504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
    Fujiwara S; Terai Y; Tsunetoh S; Sasaki H; Kanemura M; Ohmichi M
    J Gynecol Oncol; 2015 Oct; 26(4):311-9. PubMed ID: 26197776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
    Hsyu PH; Pignataro DS; Matschke K
    Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
    del Giglio A; Soares HP; Caparroz C; Castro PC
    Cancer; 2000 Dec; 89(11):2301-8. PubMed ID: 11147601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.